EVP/CLO Herdman sold 12,846 shares of RARE at $42.10 for $540,816.60; stock now -30.8% from 52-week high amid -$133.5M net loss
Karah Herdman, EVP and Chief Legal Officer of Ultragenyx Pharmaceutical, sold 12,846 shares at $42.10 on March 3, 2025, reducing holdings by 14.6% from 88,133 to 75,287 shares. The company reported a net income of $-133,516,000.00 against quarterly revenue of $139,494,000.00, underscoring persistent unprofitability despite annual revenue growth of 29.0%. The stock has declined -30.8% from its 52-week high of $59.36 and currently trades at $41.10, just below the transaction price. This sale by a senior officer occurs within a context of deteriorating stock performance and ongoing losses at a $3.8B market-cap biopharmaceutical company—a pattern relevant to observers monitoring execution and financial health at unprofitable drug developers.